February 23, 2010 – Experts in anti-platelet therapy will offer their insights and interpretations on emerging agents in comparison to current therapy at an evening session during ACC 2010 from 6:30-9:15 p.m., Sunday, March 14 at the Hyatt Regency Atlanta, 265 Peachtree St., NE, Atlanta.
While dual oral anti-platelet therapy with aspirin and a thienopyridine is a standard treatment in patients with acute coronary syndromes (ACS) and after percutaneous coronary intervention (PCI), many questions remain about its optimal use. Due to the need for improved anti-platelet therapy, new agents are presently under investigation.
Speakers will discuss choices in therapy, current evidence, new guidelines and the risk of ischemic and bleeding complications. They will also discuss evidence related to proton pump inhibitors (PPIs).
The faculty includes Deepak Bhatt, M.D. (chair); ?Jeffrey Anderson, M.D.;?Dominick Angiolillo, M.D.;?Richard Becker, M.D.;?Marc Sabatine, M.D., MPH; ?Lars Wallentin, M.D., Ph.D.; and?W. Douglas Weaver, M.D.
The session is sponsored by AstraZeneca.
For more information: www.symposiareg.com/2101